SEARCH

SEARCH BY CITATION

References

  • 1
    Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22: 14351448
  • 2
    Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF Jr. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol 1989; 141: 2229
  • 3
    Parmar MK, Freedman LS, Hargreave TB, Tolley DA. Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J Urol 1989; 142: 284288
  • 4
    Reading J, Hall RR, Parmar MK. The application of a prognostic factor analysis for Ta.T1 bladder cancer in routine urological practice. Br J Urol 1995; 75: 604607
  • 5
    Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466477
  • 6
    Ali-El-Dein B, Sarhan O, Hinev A, Ibrahiem EI, Nabeeh A, Ghoneim MA. Superficial bladder tumours: analysis of prognostic factors and construction of a predictive index. BJU Int 2003; 92: 393399
  • 7
    Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54: 303314
  • 8
    Van Rhijn BWG, Zuiverloon TCW, Vis AN et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non–muscle-invasive bladder cancer. Eur Urol 2010; 58: 433441
  • 9
    Hernández V, De La Peña E, Martin MD, Blázquez C, Diaz FJ, Llorente C. External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer. World J Urol 2011; 29: 409414
  • 10
    Fernandez-Gomez J, Madero R, Solsona E et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. Eur Urol 2011; 60: 423430
  • 11
    Ali-El-Dein B, Baraka TS, Nabeeh A, Ibrahiem E-H. Validation of Sylvester predictive model in cases of progression on top of non-muscle invasive bladder TCC. Eur Urol Suppl 2010; 9: 324 (abstract 1036)
  • 12
    Hemanek PS , Sobin LH eds. UICC–International Union Against Cancer. TNM Classification of Malignant Tumors, 4th edn. Heidelberg, Germany: Springer-Verlag, 1987
  • 13
    Mostofi K, Sobin LH. Histologic Typing of Urinary Bladder Tumors. International Histological Classification of Tumors. Geneva, Switzerland: World Health Organization, 1973
  • 14
    Dalesio O, Schulman CC, Sylvester R et al. Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group. J Urol 1983; 129: 730733
  • 15
    Mulders PF, Meyden AP, Doesburg WH, Oosterhof GO, Debruyne FM. Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. The Dutch South-Eastern Urological Collaborative Group. Br J Urol 1994; 73: 403408
  • 16
    Allard P, Bernard P, Fradet Y, Têtu B. The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br J Urol 1998; 81: 692698
  • 17
    Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodríguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000; 163: 7378
  • 18
    Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004; 93: 485490
  • 19
    Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006; 67: 12161223
  • 20
    Malmström PU, Sylvester RJ, Crawford DE et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non–muscle-invasive bladder cancer. Eur Urol 2009; 56: 247256
  • 21
    Gontero P, Bohle A, Malmstrom PU et al. The role of bacillus Calmette-Guérin in the treatment of non–muscle-invasive bladder cancer. Eur Urol 2010; 57: 410429
  • 22
    Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 19641970
  • 23
    Andius P, Johansson SL, Holmäng S. Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. Urology 2007; 70: 758762
  • 24
    Lammers RJ, Witjes WP, Hendricksen K, Caris CT, Janzing-Pastors MH, Witjes JA. Smoking status is a risk factor for recurrence after transurethral resection of non–muscle invasive bladder cancer. Eur Urol 2011; 60: 713720